Derived from Current Agreements, the partnering scorecard gives an instant overview of the top partnering deals in the life sciences by year since 2010.
The following article contains a snapshot of the largest deals by value for the year.
Our Current Agreements database stores and categorizes deal data dating as far back as 2000 saving you valuable time on your deal making research activities.
|Searching for more deal information? Current Partnering offers the following options: |
Top partnering deals of 2020 valued at over US$500m.
|AstraZeneca, Daiichi Sankyo||Jul 2020||6000||Development and licensing agreement for DS-1062|
Daiichi Sankyo has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in phase 1 clinical development for non-small cell lung cancer and triple negative breast cancer.
Daiichi Sankyo and AstraZeneca will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights.
Daiichi Sankyo will manufacture and supply DS-1062.
AstraZeneca will pay Daiichi Sankyo an upfront payment of $1 billion, of which $350 million is due upon execution, $325 million after 12 months and $325 million after 24 months.
Contingent payments of up to $5 billion include $1 billion for achievement of future regulatory milestones, and $4 billion for sales-related milestones.
Total payments under the agreement have the potential to reach up to $6 billion.
Daiichi Sankyo and AstraZeneca will share equally development and commercialization costs as well as profits from DS-1062 worldwide, except for Japan.
Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates.
AstraZeneca is expected to book sales in other markets worldwide, including China, Australia, Canada and Russia.
The upfront payment and regulatory milestones will be booked as revenue over the period in which Daiichi Sankyo has contractual performance obligations under this collaboration.
Impact on Daiichi Sankyo’s consolidated financials for fiscal year ending March 31, 2021 will be announced at an appropriate time in the future.
The collaboration is expected to enhance the corporate and shareholder value for Daiichi Sankyo over the mid- to long-term.
|Merck and Co, Seattle Genetics||Sep 2020||4200||Collaboration, co-development and licensing agreement for ladiratuzumab vedotin|
Seattle Genetics and Merck announced a strategic oncology collaboration.
The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting LIV-1, which is currently in phase 2 clinical trials for breast cancer and other solid tumors.
The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.
Seattle Genetics will receive a $600 million upfront payment and Merck will make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share.
Seattle Genetics is eligible for progress-dependent milestone payments of up to $2.6 billion.
Seattle Genetics and Merck will collaborate and equally share costs on the global development of ladiratuzumab vedotin and other LIV-1-targeting ADCs.
The companies have agreed to jointly develop and share future costs and profits for ladiratuzumab vedotin on a 50:50 basis worldwide.
Merck will pay Seattle Genetics $600 million upfront and make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share.
In addition, Seattle Genetics will be eligible to receive up to $2.6 billion in milestone payments, including $850 million in development milestones and $1.75 billion in sales milestones.
The companies will jointly develop and commercialize ladiratuzumab vedotin and equally share profits worldwide.
The companies will co-commercialize in the U.S. and Europe.
Seattle Genetics will be responsible for marketing applications for approval in the U.S. and Canada, and will record sales in the U.S., Canada and Europe.
Merck will be responsible for marketing applications for approval in Europe and in countries outside the U.S. and Canada, and will record sales in countries outside the U.S., Europe and Canada.
Including the upfront payment, equity investment proceeds and potential milestone payments, Seattle Genetics is eligible to receive up to $4.2 billion.
|Alteogen||Jun 2020||3881||Licensing agreement for Hybrozyme technology to enable subcutaneous administration of biologic products|
Alteogen has entered into a non-exclusive, global license agreement with a Top Ten Pharmaceutical Company, to use ALT-B4, Alteogen’s novel hyaluronidase- derived utilizing the Hybrozyme technology.
ALT-B4 is a proprietary recombinant human hyaluronidase enzyme that enables large-volume subcutaneous administration of biologics that would otherwise be administered as an IV injection.
Alteogen has granted worldwide rights for TTPC to develop multiple products in combination with ALT-B4.
Alteogen will receive an initial payment of USD 16 Million and is also eligible to receive additional milestones upon TTPC’s achievement of specified development, regulatory and sales milestones, totaling up to USD 3.865 Billion for the initial products under this agreement.
TTPC may in the future elect to develop additional products in combination with ALT-B4 upon achievement of the pre-specified milestone. Alteogen will be responsible for regulatory development and commercial supply of ALT-B4.
|Abbvie, Genmab||Jun 2020||3800||Collaboration, co-development, licensing and co-promotion agreement for bispecific antibody products, including epcoritamab|
AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
The companies will partner to develop Genmab's next-generation bispecific antibody programs, epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4.
The collaboration combines Genmab's world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with AbbVie's deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.
The discovery research collaboration will combine proprietary antibodies from both companies along with Genmab's DuoBody technology and AbbVie's payload and ADC technology to select and develop up to four additional differentiated next-generation antibody-based product candidates, potentially across both solid tumors and hematological malignancies.
Genmab's DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells.
AbbVie's ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
This collaboration will provide for the joint development and commercialization of the three bispecific antibody therapeutic candidates.
For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales.
For DuoHexaBody-CD37, DuoBody-CD3x5T4 and any product candidates developed as a result of the companies' discovery research collaboration, Genmab and AbbVie will share responsibilities for global development and commercialization in the U.S. and Japan.
Genmab retains the right to co-commercialize these products, along with AbbVie, outside of the U.S. and Japan.
For the discovery research partnership, Genmab will conduct Phase 1 studies for these programs.
AbbVie retains the right to opt-in to program development.
AbbVie will pay Genmab USD 750 million in upfront payment with the potential for Genmab to receive up to USD 3.15 billion in additional development, regulatory and sales milestone payments for all programs as well as tiered royalties between 22% and 26% on net sales for epcoritamab outside the U.S. and Japan.
Except for these royalty-bearing sales, the parties share in pre-tax profits from the sale of products on a 50:50 basis.
Included in these potential milestones are up to USD 1.15 billion in payments related to clinical development and commercial success across the three existing bispecific antibody programs.
In addition, if all four next-generation antibody product candidates developed as a result of the discovery research collaboration are successful, Genmab is eligible to receive up to USD 2.0 billion in option exercise and success-based milestone payments.
|Fate Therapeutics, Janssen Biotech||Apr 2020||3100||Collaboration, option, licensing and co-promotion agreement for iPSC-derived cell-based cancer immunotherapies|
Fate Therapeutics announced a global collaboration and option agreement with Janssen Biotech.
Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets.
The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.
The Company will receive $50 million in cash and $50 million from the purchase by Johnson & Johnson Innovation of newly issued shares of the Company’s common stock at a price per share of $31.00.
Janssen will also reimburse the Company for all activities conducted under the collaboration.
The Company will advance candidates under the collaboration to the filing of an Investigational New Drug (IND) application, after which Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens.
The Company will be primarily responsible for the manufacture of collaboration candidates, the cost of which will be paid for by Janssen.
The Company is eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.
In addition, the Company has the right to elect to co-commercialize each collaboration candidate in the U.S. and share equally in profits and losses in the U.S., subject to its payment of certain clinical development costs and adjustments in milestone and royalty payments.
|Bristol-Myers Squibb, Repare Therapeutics||May 2020||3065||Collaboration agreement for SNIPRx synthetic lethal discovery platform to identify multiple oncology drug candidates|
Repare Therapeutics has entered into an exclusive, worldwide research collaboration with Bristol Myers Squibb.
Under the terms of the agreement, the companies will leverage Repare’s proprietary, CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx, to jointly identify multiple synthetic lethal precision oncology targets for drug candidates.
Repare will grant BMS exclusive worldwide rights to develop and commercialize therapeutics for select validated synthetic lethal precision oncology targets discovered under the collaboration.
BMS will make an upfront payment of $65 million which includes a $15 million equity investment in Repare.
Repare will be eligible to receive up to approximately $3 billion in license fees, discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of each product commercialized by BMS.
|WuXi Biologics||Feb 2020||3000||Manufacturing agreement for vaccine products|
WuXi Biologics announced that WuXi Vaccines has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion USD, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial vaccine products for the global market.
WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC).
The facility will be dedicated to manufacture one of its partner's vaccine products for the global market.
The new facility is expected to be operational in 2022.
|Biogen, Sangamo BioSciences||Feb 2020||2720||Collaboration and licensing agreement for gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular, and other neurological diseases|
Biogen and Sangamo Therapeutics have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.
The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases.
Biogen has exclusive global rights to ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a third undisclosed neuromuscular disease target.
In addition, Biogen has exclusive rights to nominate up to nine additional undisclosed targets over a target selection period of five years.
Sangamo will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs targeting therapeutically relevant genes.
Biogen will then assume responsibility and costs for the investigational new drug-enabling studies, clinical development, related regulatory interactions, and global commercialization.
Sangamo will be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity.
Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products.
Sangamo will receive $350 million comprised of $125 million in a license fee payment and $225 million from the sale of new Sangamo stock, or approximately 24 million shares at $9.21 per share.
Sangamo may receive up to $2.37 billion in other development, regulatory, and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1,445 million in first commercial sale and other sales-based milestone payments.
Sangamo will also be eligible to receive from Biogen tiered high single digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.
|Nurix, Sanofi||Jan 2020||2555||Collaboration, option, co-development and co-promotion agreement for targeted protein degradation therapies|
Nurix Therapeutics announced a global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas.
Nurix will utilize its proprietary drug discovery platform, DELigase, that integrates its DNA-encoded libraries (DEL) and its unparalleled portfolio of E3 ligases to create small molecules designed to induce degradation of three specified drug targets, with an option by Sanofi to expand to a total of five targets.
Sanofi will have exclusive rights and be responsible for clinical development and commercialization of drug candidates resulting from the work while Nurix will retain the option to co-develop and co-promote up to two products in the United States under certain conditions.
The collaboration excludes Nurix’s lead degradation programs for which Nurix retains all rights.
Nurix will receive an upfront payment of $55 million and subsequent payments upon expansion of the number of targets to be included in the collaboration.
In addition, Nurix will be eligible to receive up to approximately $2.5 billion in total payments based on the successful completion of certain research, pre-clinical, clinical, regulatory and sales milestones.
For those programs that Nurix exercises its option to co-develop and co-promote, the parties will split U.S. profits and losses evenly and Nurix will be eligible to receive royalties on ex-U.S. net sales on all optioned products.
|Astex Pharmaceuticals, Merck and Co, Taiho||Jan 2020||2550||Collaboration, licensing, option and co-promotion agreement for small molecule inhibitors against several drug targets including KRAS oncogene|
Merck announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical and Astex Pharmaceuticals focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.
Merck, Taiho and Astex will combine preclinical candidates and their data with knowledge and expertise from their respective research programs.
In exchange for providing Merck an exclusive global license to their small molecule inhibitor candidates, Taiho and Astex will receive an aggregate upfront payment of $50 million and will be eligible to receive approximately $2.5 billion contingent upon the achievement of preclinical, clinical, regulatory and sales milestones for multiple products arising from the agreement, as well as tiered royalties on sales.
Merck will fund research and development and will be responsible for commercialization of products globally.
Taiho has retained co-commercialization rights in Japan and an option to promote in specific areas of South East Asia.
|Sanofi-Pasteur, Translate Bio||Mar 2020||2329||Collaboration agreement for mRNA vaccine candidate against COVID-19|
Translate Bio announced the closing of a previously announced expansion of the collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for all infectious disease pathogens.
Translate Bio will receive $425 million in upfront payment and common stock equity investment and overall is eligible to receive up to $1.9 billion of potential milestones and other payments as well as tiered royalties on worldwide sales of developed vaccines.
Sanofi received exclusive worldwide rights for infectious disease mRNA vaccines. Sanofi will pay for all costs during the collaboration term.
Sanofi Pasteur and Translate Bio collaborate to develop a novel mRNA vaccine for COVID-19.
This collaboration leverages an existing agreement from 2018 between the two companies to develop mRNA vaccines for infectious diseases.
|Kymera Therapeutics, Sanofi||Jul 2020||2150||Collaboration and option agreement for protein degrader therapies|
Kymera Therapeutics has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.
The companies will also partner on a second earlier stage program.
Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as well as significant royalty payments.
Kymera retains the option to participate in US development and commercialization for both programs.
This includes the ability to participate equally in the costs, profits and losses after opt-in, and to co-promote partnered products in the US.
Sanofi will make an upfront payment of $150 million in cash to Kymera for global rights to develop its small molecule IRAK4 protein degraders in inflammation and immunology indications, and a second earlier stage undisclosed program.
IRAK4 is believed to play a key role in multiple immune-inflammatory diseases, including hidradenitis suppurativa, atopic dermatitis and rheumatoid arthritis.
Kymera will advance the IRAK4 program through Phase 1 clinical trials; Sanofi will assume clinical development and commercialization responsibilities thereafter.
Sanofi will lead all clinical development activities for the second program.
Kymera will have the option to participate in the development of both programs in the US during clinical development.
Kymera will retain global rights to its IRAK4 program in oncology indications.
|Biogen, Denali Therapeutics||Aug 2020||2150||Collaboration, licensing, co-development and co-prmotion agreement for LRRK2 program for Parkinson’s disease and Certain TV platform-enabled programs for neurodegenerative diseases|
Biogen and Denali Therapeutics have signed a binding agreement to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.
Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative diseases leveraging Denali’s Transport Vehicle (TV) technology platform to cross the blood-brain barrier (BBB).
Biogen will collaborate with Denali to co-develop and co-commercialize Denali’s small molecule inhibitors of LRRK2 for Parkinson’s disease.
Biogen and Denali will co-commercialize the LRRK2 product in the U.S. and China, and Biogen will commercialize in all other markets.
DNL151 has been selected to progress into late stage clinical studies expected to commence in 2021.
In addition to the LRRK2 program, Biogen will also receive an exclusive option to license two preclinical programs from Denali’s TV platform, which aims to improve brain uptake of biotherapeutics, including its Antibody Transport Vehicle (ATV): Abeta program (ATV enabled anti-amyloid beta program) and a second program utilizing its TV technology.
Biogen will have right of first negotiation on two additional TV-enabled therapeutics, currently at a preclinical stage, should Denali decide to seek a collaboration for such programs.
Denali’s TV platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes, proteins and oligonucleotides across the BBB after intravenous administration.
Biogen will make an upfront payment to Denali of $560 million and make a $465 million equity investment in Denali from the purchase of 13.3 million newly issued shares of Denali common stock at approximately $34.94 per share, representing 11.2 percent of Denali’s pro-forma outstanding stock.
Should the LRRK2 program achieve certain development and commercial milestones, Denali will be eligible to receive up to $1.125 billion in potential milestone payments.
In the LRRK2 collaboration, Biogen and Denali will share responsibility and costs for global development (60 percent Biogen; 40 percent Denali), and will share responsibility and costs as well as profits and losses for commercialization in the U.S. (50 percent Biogen; 50 percent Denali) and China (60 percent Biogen; 40 percent Denali).
Outside the U.S. and China, Biogen will be responsible for commercialization and pay Denali tiered royalties.
|Genentech, Roche, UCB||Jul 2020||2120||Collaboration and licensing agreement for UCB0107 antibody treatment for people living with Alzheimer's Disease|
UCB announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech for the global development and commercialization of UCB0107 in Alzheimer's Disease.
The transaction remains subject to obtaining antitrust clearance and other customary closing conditions.
UCB will provide an exclusive, world-wide license to Roche and Genentech to develop and commercialize UCB0107 in AD.
UCB will receive an initial upfront payment of US $120 million.
UCB will fund and perform a proof-of-concept study in AD and, upon availability of the results of that study, Genentech has the right to progress with the development or return full rights back to UCB.
After Genentech's decision to proceed with further clinical development, UCB will be eligible to receive further potential cost reimbursement, development and sales milestone payments as well as royalties with a total potential consideration approaching US $2 billion upon receipt of certain regulatory approvals and satisfying certain clinical and sales milestones.
|Innovent Biologics, Roche||Jun 2020||2100||Collaboration agreement for multiple products including cellular therapies and bispecific antibodies|
Innovent Biologics announced a strategic research and development collaboration with Roche covering multiple cell therapies and bispecific antibodies.
The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers.
Innovent will pay upfront, development and commercial milestone payments, and royalties, to non-exclusively access certain Roche technologies that enable the discovery and development of specific 2:1 T-cell bispecific antibodies (TCB) and the universal CAR-T platform.
Innovent will create, develop, manufacture, and commercialize the products. Roche retains an option right to license each product for ex-China development and commercialization.
Should Roche exercise all of its options, it will pay option exercise payments totaling $140 million plus additional development, approval, and sales milestone payments up to $1.96 billion if all products are successfully developed and commercialized.
Roche will pay double-digit up to mid teen percentage royalties on each product.
|CSL Behring, UniQure||Jun 2020||2050||Licensing agreement for AMT-061 (etranacogene dezaparvovec)|
uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B.
Etranacogene dezaparvovec consists of an AAV5 viral vector carrying a gene cassette with the patent-protected Padua variant of Factor IX (FIX-Padua).
uniQure will receive a $450 million upfront cash payment and be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones.
uniQure will also be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percentage of net product sales arising from the collaboration.
|Neurocrine Biosciences, Takeda Pharmaceutical||Jun 2020||2015||Collaboration and licensing agreement for therapies for psychiatric disorders|
Neurocrine Biosciences and Takeda Pharmaceutical announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline.
Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.
Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration.
Takeda will receive a total of $120 million USD in upfront cash.
Takeda will be entitled to development milestones of up to $495 million USD, commercial milestones of up to $1.4 billion USD and up to double-digit royalties on net sales.
At certain development events, Takeda may elect to opt in or out of a 50:50 profit share on all clinical programs on an asset-by-asset basis.
For any asset in which Takeda is participating in a 50:50 profit share arrangement, Takeda will not be eligible to receive development or commercial milestones.
|Incyte, MorphoSys||Jan 2020||2000||Collaboration, licensing and co-promotion agreement for Tafasitamab|
MorphoSys and Incyte have entered into a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary anti-CD19 antibody tafasitamab (MOR208) globally.
Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B cell malignancies.
MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.
MorphoSys will receive an upfront payment of $750 million and, in addition, Incyte will make an equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS) of MorphoSys at a premium to the share price at signing of the agreement.
Depending on the achievement of certain developmental, regulatory and commercial milestones, MorphoSys will be eligible to receive milestone payments amounting to up to $1.1 billion.
MorphoSys will also receive tiered royalties on ex-U.S. net sales of tafasitamab in a mid-teens to mid-twenties percentage range of net sales.
In the U.S., MorphoSys and Incyte will co-commercialize tafasitamab, with MorphoSys leading the commercialization strategy and booking all revenues from sales of tafasitamab.
Incyte and MorphoSys will be jointly responsible for commercialization activities in the U.S. and will share profits and losses on a 50:50 basis.
Outside the U.S., Incyte will have exclusive commercialization rights, and will lead the commercialization strategy and book all revenues from sales of tafasitamab, paying MorphoSys royalties on ex-U.S. net sales.
Furthermore, the companies will share development costs associated with global and U.S.-specific trials at a rate of 55% (Incyte) to 45% (MorphoSys); Incyte will cover 100% of the future development costs for trials that are specific to ex-U.S. countries.
Both parties have agreed to co-develop tafasitamab broadly in relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL), frontline DLBCL as well as additional indications beyond DLBCL, such as follicular lymphoma (FL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL).
Incyte will be responsible for initiating a combination study of its investigational PI3K-delta inhibitor parsaclisib and tafasitamab in r/r B cell malignancies.
Further, Incyte will be responsible for leading any potential registration-enabling studies in CLL and a phase 3 trial in r/r FL/MZL. MorphoSys will continue to be responsible for its currently ongoing clinical trials of tafasitamab in non-Hodgkin lymphoma (NHL), CLL, r/r DLBCL and frontline DLBCL. The parties will share responsibility in starting additional global trials, and Incyte intends to pursue development in additional territories including Japan and China.
MorphoSys recently submitted a Biologics License Application (BLA) for tafasitamab, in combination with lenalidomide, to the U.S. Food and Drug Administration (FDA) for the treatment of r/r DLBCL; the FDA decision regarding a potential approval is expected by mid-2020.
The submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in r/r DLBCL is planned for mid-2020.
|Alnylam Pharmaceuticals, Blackstone Medical||Apr 2020||2000||Royalty financing agreement to facilitate RNAi therapeutics|
Blackstone Medical and Alnylam Pharmaceuticals have entered into a broad strategic collaboration under which Blackstone will provide up to $2 billion to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases.
The deal is anchored by Blackstone’s purchase of 50 percent of the royalties owed to Alnylam on global sales of inclisiran, an investigational RNAi therapeutic for the treatment of hypercholesterolemia, currently under review by the U.S. Food and Drug Administration.
Inclisiran is a twice-a-year, subcutaneously injected RNAi therapeutic that has been shown in a comprehensive Phase 3 program to reduce low-density lipoprotein (LDL) or “bad” cholesterol with an acceptable safety profile.
If approved, this medicine is expected to help patients lower LDL cholesterol, a major risk factor for cardiovascular disease, the leading cause of mortality in the U.S. and globally.
The strategic financing collaboration, led by Blackstone Life Sciences and GSO Capital Partners, Blackstone’s credit platform, is expected to enable Alnylam’s achievement of a self-sustainable financial profile without need for future equity financing, accelerating the commercial potential of Alnylam’s rapidly advancing product portfolio.
The investment by multiple Blackstone businesses will support the development and delivery of promising medicines to the patients who need them and is one of the largest ever private financings of a biotech company.
The transaction includes the inclisiran royalty monetization, corporate debt, purchase of Alnylam equity, and funding for certain R&D activities related to the clinical advancement of two Alnylam investigational RNAi therapeutic programs in cardiovascular disease.
Specifically, the transaction is comprised of the following components:
$1 billion in committed payments, led by Blackstone Life Sciences, to acquire 50 percent of Alnylam’s royalties and commercial milestones for inclisiran;
Up to $750 million in a first lien senior secured term loan led by GSO;
Up to $150 million from Blackstone Life Sciences for development of Alnylam’s cardiometabolic programs vutrisiran and ALN-AGT (to be established based upon a non-binding letter of intent);
$100 million purchase of Alnylam common stock.
|BioNTech, Pfizer, US Government||Jul 2020||1950||Supply agreement for mRNA-based SARS-CoV-2 vaccine|
Pfizer and BioNTech announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021.
Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration.
The U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval.
The U.S. government also can acquire up to an additional 500 million doses.
|Abbvie, I-mab||Sep 2020||1940||Collaboration and licensing agreement for differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)|
AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers.
In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.
The collaboration established today provides AbbVie with an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab. Both companies will collaborate to design and conduct further global clinical trials to evaluate lemzoparlimab in multiple cancers.
I-Mab retains all rights to develop and to commercialize lemzoparlimab in mainland China, Macau and Hong Kong.
The collaboration also allows for potential collaboration on future CD47-related therapeutic agents.
Each party will have the opportunity subject to further licenses to explore each other's related programs in their respective territories.
The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply.
The collaboration will accelerate I-Mab's establishment of commercial production operations in China.
AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab, along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million.
I-Mab will be eligible to receive up to $1.74 billion in success-based milestone payments for lemzoparlimab, of which $840 million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones.
Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China.
|Arcus Biosciences, Gilead Sciences||May 2020||1900||Co-development and co-promotion agreement for next-generation cancer immunotherapies|
Gilead Sciences and Arcus Biosciences have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline.
The agreement will also provide ongoing funding to support Arcus’s research and development programs.
Arcus will receive $375 million upon closing, consisting of a $175 million upfront payment and a $200 million equity investment from Gilead.
Arcus is eligible to receive up to $1.225 billion in opt-in and milestone payments with respect to its current clinical product candidates.
Gilead will gain access to Arcus’s current and future investigational immuno-oncology products through the agreement, as Gilead continues to expand its presence in the field.
This includes immediate rights to zimberelimab, as well as the right to opt-in to all other current Arcus clinical candidates, which include AB154, AB928 and AB680, upon payment of an opt-in fee that ranges from $200 million to $275 million per program, after delivery of a qualifying data package.
If Gilead opts-in to the AB154 program, Arcus is eligible to receive up to $500 million in potential future U.S. regulatory approval milestones.
Gilead will receive the right to opt-in to all other programs that emerge from Arcus’s research portfolio over the next 10 years, upon payment of an opt-in fee of $150 million per program after Arcus’s delivery of a qualifying data package.
Upon Gilead’s exercise of its option for a program, unless Arcus opts out according to terms of the agreement, the companies will co-develop and share global development costs and will co-commercialize and share profits in the United States.
Gilead will obtain exclusive rights to commercialize any optioned programs outside of the U.S., subject to any rights of Arcus’s existing partners, and for which Gilead will pay to Arcus tiered royalties ranging from high-teens to low twenties.
Gilead will further provide ongoing research and development support of up to $400 million over the collaboration term.
Gilead will have the right to appoint two individuals to Arcus’s Board of Directors upon closing of the transaction.
Gilead’s $200 million equity investment will be at a price per share of $33.54. Additionally, Gilead will have the right to purchase additional shares from Arcus, up to a maximum of 35% of the outstanding voting stock of Arcus over the course of the next five years, at a 20% premium at the time Gilead exercises such option, or, if greater, at the initial purchase price per share.
|Gilead Sciences, Pionyr Immunotherapeutics||Jun 2020||1745||Option agreement to acquire Pionyr Immunotherapeutics|
Gilead Sciences announced that for $275 million the company will acquire a 49.9 percent equity interest in Pionyr Immunotherapeutics, and an exclusive option to purchase the remainder of Pionyr.
Pionyr’s shareholders may receive up to an additional $1.47 billion in option exercise fees and future milestone payments.
Pionyr’s shareholders will receive $275 million upon closing.
Gilead will receive 49.9 percent of the common stock of Pionyr and an exclusive option to purchase the remaining equity.
Gilead may exercise its exclusive option upon completion of Phase 1b studies for PY314 and PY159, or at an earlier time if Gilead chooses to do so, for a $315 million option exercise fee and up to $1.15 billion in potential future milestone payments.
Gilead will provide Pionyr with additional funding for the PY314 and PY159 clinical programs, as well as ongoing research and development programs.
Gilead will have the right to nominate one individual to Pionyr’s Board of Directors upon closing of the transaction.
Gilead and the other stockholders of Pionyr will jointly select and nominate one independent individual to Pionyr’s Board of Directors.
|Bicycle Therapeutics, Genentech||Feb 2020||1730||Collaboration and licensing agreement for Bicycle-based immuno-oncology therapies|
Bicycle Therapeutics has entered into a strategic collaboration agreement with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies.
By entering into this early discovery collaboration with Genentech, Bicycle will be exploring its technology on a wider range of immuno-oncology targets, combining the expertise of both companies.
Bicycle brings its proprietary discovery platform, which allows rapid screening of novel targets to identify Bicycles and the ability to readily conjugate these together to create novel molecules that may overcome the potential limitations of other modalities.
Genentech brings to the collaboration its knowledge of immuno-oncology drug discovery and emerging target biology, as well as its development and commercialization expertise.
Genentech and Bicycle will collaborate on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets.
Bicycle will be responsible for discovery research and early pre-clinical development up to candidate selection, and Genentech will be responsible for further development and commercialization upon the selection of candidates.
None of Bicycle’s wholly owned oncology pipeline, including its immuno-oncology candidates, are included in the collaboration.
Bicycle will receive a $30 million upfront payment.
The upfront payment and potential discovery, development, regulatory and commercial-based milestone payments could total up to $1.7 billion.
Bicycle will also be eligible to receive tiered royalties on Bicycle-based medicines commercialized by Genentech.
|Blueprint Medicines, Genentech, Roche||Jul 2020||1702||Collaboration, licensing and co-promotion agreement for Pralsetinib|
Blueprint Medicines has entered into a global collaboration with Roche and Genentech to develop and commercialize pralsetinib, an investigational once-daily oral precision therapy for the treatment of people with cancer driven by oncogenic RET alterations, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), other thyroid cancers and other solid tumors.
Blueprint Medicines and Genentech will co-commercialize pralsetinib in the U.S. and Roche will obtain exclusive commercialization rights for pralsetinib outside of the U.S., excluding Greater China.
The companies also plan to expand development of pralsetinib in multiple treatment settings and explore development of a next-generation RET inhibitor as part of this collaboration.
The collaboration combines Blueprint Medicines' pralsetinib and precision therapy expertise with Roche's global reach, integrated personalized healthcare capabilities and portfolio of cancer therapies.
Marketing applications for pralsetinib are submitted or planned for RET fusion-positive NSCLC, RET mutation-positive MTC and RET fusion-positive thyroid cancer in the U.S., Europe and other geographies.
Blueprint Medicines will grant Roche an exclusive worldwide license excluding Greater China and the U.S., and a co-exclusive license in the U.S. to develop and commercialize pralsetinib.
In addition, Roche will have the right to opt in to a next-generation RET compound co-developed under the collaboration.
Blueprint Medicines will receive $775 million in upfront payments, including a cash payment of $675 million and an equity investment by Roche of $100 million in Blueprint Medicines' common stock at a purchase price of $96.57 per share.
Blueprint Medicines will be eligible to receive up to an additional $927 million in contingent payments, including specified development, regulatory and sales-based milestones for pralsetinib and any licensed product containing a next-generation RET compound.
In the U.S., Blueprint Medicines and Genentech will work together to co-commercialize pralsetinib, with the companies equally sharing responsibilities, profits and losses.
In addition, Blueprint Medicines is eligible to receive tiered royalties ranging from high-teens to mid-twenties on annual net sales of pralsetinib outside the U.S.
Blueprint Medicines and Roche have agreed to co-develop pralsetinib globally in RET-altered solid tumors, including NSCLC, MTC and other thyroid cancers, as well as other solid tumors.
The companies will share global development expenses based on pre-specified cost-sharing.
|Astellas Pharma, CytomX Therapeutics||Mar 2020||1680||Collaboration, licensing, option and co-promotion agreement for Probody T-cell engaging bispecific therapies for cancer|
CytomX Therapeutics and Astellas Pharma have entered into a strategic collaboration agreement focused on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.
The parties will utilize CytomX’s Probody therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules.
CytomX and Astellas will collaborate on several initial programs.
CytomX will lead research and discovery activities, up to clinical candidate selection, that will be funded by Astellas.
Astellas will lead and fund preclinical and clinical development and commercialization activities.
Astellas will make an upfront cash payment of $80 million to CytomX with CytomX eligible to receive future preclinical, clinical and commercial milestones of over $1.6 billion.
CytomX is also eligible to receive tiered royalties on global net sales that range from high-single digits to mid-teens.
For a specified number of targets, prior to the initiation of the first pivotal clinical trial for a product directed toward such target, CytomX may exercise an option to co-fund a pre-determined portion of clinical development costs.
For these products, CytomX is eligible to receive a pre-specified portion of profits in the United States and tiered low-double digit to mid-teen percentage royalties on net sales outside of the United States.
CytomX may later elect to co-commercialize the products directed toward such targets in the United States.
|Affinia Therapeutics, Vertex Pharmaceuticals||Apr 2020||1600||Collaboration, option and licensing agreement for AAV capsids for genetic therapies|
Vertex Pharmaceuticals and Affinia Therapeutics have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases.
Affinia Therapeutics’ proprietary AAVSmartLibrary and associated technology provides capsids for improved tissue tropism, manufacturability and pre-existing immunity.
The collaboration will leverage Affinia Therapeutics’ capsid engineering expertise and Vertex’s scientific, clinical and regulatory capabilities to accelerate the development of genetic therapies for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF).
Affinia Therapeutics will apply its vector design and engineering technologies to develop novel capsids with improved properties.
The agreement provides Vertex an exclusive license under Affinia Therapeutics’ proprietary technology and intellectual property (IP) in DMD and DM1 with an exclusive option to license rights for CF and an additional undisclosed disease.
The scope of the agreement covers all genetic therapy modalities in these diseases.
Affinia Therapeutics will be eligible to receive over $1.6 billion in upfront and development, regulatory and commercial milestones, including $80 million in upfront payments and research milestones that will be paid during the research term, plus tiered royalties on future net global sales on any products that result from the collaboration.
Affinia Therapeutics will be responsible for the discovery of capsids that meet certain pre-determined criteria.
Vertex will be responsible for and will fund the design and manufacturing of genetic therapies incorporating the selected capsids, preclinical and clinical development efforts, and commercialization of any approved products in the licensed diseases.
|Novavax, UK Government||Jul 2020||1600||Contract service agreement for vaccine for COVID-19|
Novavax has been selected to participate in Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021.
Novavax has been awarded $1.6 billion by the federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M adjuvant.
Novavax will demonstrate it can rapidly stand up large-scale manufacturing and transition into ongoing production, including the capability to stockpile and distribute large quantities of NVX-CoV2373 when needed.
The agreement will fund the late-stage clinical studies necessary to determine the safety and efficacy of NVX-CoV2373, including a pivotal Phase 3 clinical trial with up to 30,000 subjects beginning in the fall of 2020.
|Gilead Sciences, Tizona Therapeutics||Jul 2020||1550||Option agreement for Tizona|
Gilead Sciences announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics.
Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional $1.25 billion, including an option exercise fee and potential future milestone payments.
Gilead can exercise its option to acquire the remainder of Tizona following the readout of a Phase 1b study of Tizona’s investigational antibody, TTX-080, or earlier if Gilead decides to do so.
TTX-080, discovered by Tizona, is a potential first-in-class medicine that targets HLA-G, a novel and emerging immune checkpoint expressed across multiple tumor types.
The expression pattern of HLA-G often appears distinct from that of PD-(L)1, suggesting potential utility to address tumors that do not respond to current anti-PD-(L)1 treatments and to deepen responses in tumors that are sensitive to anti-PD-(L)1 therapies.
Tizona equity holders will receive $300 million upon closing.
Gilead will obtain a 49.9 percent equity stake and an exclusive option to purchase the remaining equity exercisable following the completion of Phase 1b studies for TTX-080, or earlier if Gilead chooses.
Tizona equity holders will be eligible to receive up to $1.25 billion in an option exercise fee and potential future milestone payments.
Gilead will also provide funding to support Tizona’s ongoing research and development to advance its novel pipeline.
Gilead will have the right to appoint two individuals to Tizona’s Board of Directors upon closing of the transaction.
|Amunix, Hoffmann La Roche, Roche||Jan 2020||1540||Licensing agreement for technology platform, XTEN, to discover and develop non-oncology therapeutics|
Amunix Pharmaceuticals has provided a technology license to F. Hoffmann-La Roche and Hoffmann-La Roche to utilize Amunix’s technology platform, XTEN, to discover and develop non-oncology therapeutics against certain undisclosed targets.
This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.
Amunix will receive a $40 million upfront payment from Roche.
Amunix may also receive up to $1.5 billion in payments from Roche associated with the achievement of certain developmental and sales milestones, plus royalties on sales of commercialized products.
|Gilead Sciences, Second Genome||Apr 2020||1538||Collaboration, option and licensing agreement for biomarker and inflammatory bowel disease drug discovery|
Gilead Sciences and Second Genome have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease (IBD).
Second Genome will utilize its proprietary Microbiome Analytics Platform to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.
This work will harness the latest insights in microbiome science to help inform patient stratification and optimize potential treatments for patients in the future.
The platform, in combination with additional discovery and development tools, will also seek to identify new targets and drug candidates relevant to IBD.
This will include the identification of up to five novel IBD targets or drug candidates over the next four years, with an option to extend the collaboration for an additional two years.
Second Genome will receive $38 million in an upfront payment, and up to approximately $300 million in success-based preclinical, clinical, regulatory and commercial milestones for each of five target discovery programs as well as low double-digit royalties for any approved products.
In addition, it will receive success-based milestones for each validated biomarker delivered under the agreement.
Gilead will have the option to worldwide rights for up to five programs for all diseases as well as exclusive rights to all biomarkers developed under the collaboration.
|Moderna Therapeutics, US Government||Aug 2020||1525||Supply agreement for mRNA Vaccine Against COVID-19 (mRNA-1273)|
Moderna announced that the US government has secured 100 million doses of mRNA-1273 as part of the US government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people.
The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of mRNA-1273 including incentive payments for timely delivery of the product.
With the previous award of up to $955 million from BARDA for the development of mRNA-1273 to licensure, today’s announcement brings the U.S. government commitments for early access to mRNA-1273 to up to $2.48 billion.
Under the terms of the agreement, the U.S. government, as a part of Operation Warp Speed, will also have the option to purchase up to an additional 400 million doses of mRNA-1273 from Moderna.
The U.S. government has announced that consistent with its commitment to free access to COVID-19 vaccines, Americans will receive mRNA-1273 at no cost for the vaccine itself.
|Aro Biotherapeutics, Ionis Pharmaceuticals||Jan 2020||1400||Collaboration and licensing agreement for cell-specific delivery of antisense oligonucleotides|
Aro Biotherapeutics announced today that Ionis Pharmaceuticals has exercised an option to acquire a license to an undisclosed antisense oligonucleotide (ASO)-Centyrin drug conjugate.
Aro Biotherapeutics has entered a licensing and collaboration agreement with Ionis Pharmaceuticals through which Ionis will use Aro’s CENTYRIN technology to develop targeted cell- and tissue- specific delivery of antisense oligonucleotides (ASOs).
Under the terms of the agreement, the companies will collaborate to create unique ASO-Centyrin conjugates that are designed to achieve tissue specific, therapeutically effective gene knockdown in extra-hepatic tissues with systemic administration.
Under the terms of the agreement, the two companies have agreed to jointly work towards advancing a defined number of ASO-Centyrin drug conjugates.
Aro will be responsible for Centyrin discovery and will collaborate with Ionis to create lead ASO-Centyrin drug conjugates for further development.
Ionis will be responsible for development and will have global commercialization rights for each ASO-Centyrin drug conjugate.
The parties will also collaborate on additional discovery programs.
Aro will receive an upfront cash payment, funding to support R&D efforts, and payments associated with the achievement of specific development and commercial milestones, up to $1.4B.
In addition, Aro will receive royalties on net sales.
|Eli Lilly, Evox Therapeutics||Jun 2020||1220||Collaboration and licensing agreement for DeliverEX platform for RNA interference and antisense oligonucleotide drug payloads for neurological disorders|
Evox Therapeutics announced a research collaboration and license agreement with Eli Lilly to leverage Evox's proprietary DeliverEX platform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders.
During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies.
Any resulting candidate handover and technology transfer to Lilly will occur after pre-clinical proof of concept studies have been completed.
Evox will receive a $20 million cash up-front payment, research funding over three years, as well as a $10 million investment from Lilly in exchange for a convertible bond from the Company.
Evox will also be eligible for potential pre-clinical and clinical development, regulatory and commercial milestones of up to approximately $1.2 billion, as well as tiered royalties up to low double digits on net sales of products arising from the collaboration.
|Accent Therapeutics, AstraZeneca||Jun 2020||1155||Collaboration, option and licensing agreement for therapeutics targeting RNA-modifying proteins (RMPs) for treatment of cancer|
Accent Therapeutics and AstraZeneca will collaborate to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer.
The collaboration combines Accent’s expertise as a leader in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s industry leading expertise in oncology.
Accent will be responsible for research and development activities for a nominated preclinical program through to the end of Phase I clinical trials.
Following completion of Phase I, AstraZeneca will lead development and commercialization activities for the nominated program, with Accent having the option to jointly develop and commercialize with AstraZeneca in the US.
AstraZeneca will also have the exclusive option to license worldwide rights to two further preclinical discovery programs, for which Accent will conduct certain preclinical activities.
Accent will receive an upfront payment of $55 million and, in the event that Accent elects to jointly develop the nominated program, is eligible to receive up to $1.1 billion in additional success-based payments across all programs in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits.
In the event Accent opts into co-developing and co-commercializing the nominated program, profits and losses will be split in the US.
|GlaxoSmithKline, Immatics Biotechnologies||Feb 2020||1150||Development, licensing and option agreement for novel adoptive cell therapies|
Immatics Biotechnologies has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.
The companies will collaborate on the identification, research and development of next-generation T-Cell Receptor (TCR) Therapeutics with a focus on solid tumors.
The parties will initially develop autologous T-cell therapies with the option to add allogeneic cell therapies using Immatics’ ACTallo approach.
The companies intend to utilize proprietary TCRs identified by Immatics’ XCEPTOR TCR discovery platform and directed against two proprietary targets, which were discovered and validated by Immatics’ XPRESIDENT technology.
Immatics will receive an upfront payment of €45 Million (~$50 million) for two initial programs and is eligible to receive over $550M in development, regulatory and commercial milestone payments for each product as well as additional royalty payments.
GSK obtains an option to select additional target programs to include in the collaboration.
For each additional program, Immatics is entitled to option, milestone and royalty payments.
Immatics will have primary responsibility for the development and validation of the TCR Therapeutics up to designation of a clinical candidate.
GSK will assume sole responsibility for further worldwide development, manufacturing and commercialization of the TCR Therapeutics with the possibility for Immatics to co-develop one or more TCR Therapeutics including the conduct of the first-in-human clinical trial upon GSK’s request.
|CureVac, GlaxoSmithKline||Jul 2020||1106||Collaboration agreement for mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens|
GlaxoSmithKline and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens.
The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform.
The companies will combine their mRNA expertise on development opportunities across a range of infectious disease pathogens, selected with the potential to best leverage the advantages of this platform technology, while addressing significant unmet medical need and economic burden.
CureVac’s existing COVID-19 mRNA and rabies vaccines research programmes are not included in the collaboration.
GSK will make an equity investment in CureVac of £130m (€150m), representing close to a 10% stake, an upfront cash payment of £104m (€120m) and a one-time reimbursable payment of £26m (€30m) for manufacturing capacity reservation, upon certification of CureVac’s commercial scale manufacturing facility currently under construction in Germany.
CureVac will be eligible to receive development and regulatory milestone payments of up to £277m (€320m), commercial milestone payments of up to £329m (€380m) and tiered royalties on product sales.
GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration.
CureVac will be responsible for the preclinical- and clinical-development through Phase 1 trials of these projects, after which GSK will be responsible for further development and commercialization.
CureVac will be responsible for the GMP manufacturing of the product candidates, including for commercialization, and will retain commercialization rights for selected countries for all product candidates.
|Abpro||Mar 2020||1100||Licensing agreement for two bispecific antibodies, ABP-100 and ABP-201|
Abpro announced the formation of a strategic partnership to advance two bispecific antibodies in key Asian markets including Greater China, Japan, and South Korea.
The strategic partnership was formed with Abpro Bio.
Abpro has granted an exclusive license to Abpro Bio to develop and commercialize two of Abpro’s bispecific antibody candidates: ABP-100 and ABP-201.
ABP-100 is in development for immuno-oncology with initial indications including gastric, breast and endometrial cancers.
ABP-201 is in development for ophthalmology with initial indications inclusive of Wet AMD (age-related macular degeneration) and diabetic macular edema.
The collaboration will also leverage Abpro’s proprietary DiversImmune antibody platform for generating novel molecules.
Abpro will lead global clinical development of the bi-specific candidates and work closely with Abpro Bio.
Key terms of the agreement include:
Abpro will receive from Abpro Bio up to $1.1 billion in total payments, including a $30 million upfront equity investment, and an additional $1.05 billion based on clinical milestones, post-approval payments, and royalties as ABP-100 and ABP-201 progress through the clinical development and regulatory approval processes in Greater China, Japan, and South Korea.
Abpro Corporation’s two co-founders, Ian Chan and Eugene Chan, as well as Robert S. Langer, PhD, Institute Professor at MIT, will join the Board of Abpro Bio Ltd.
|Atomwise, Bridge Biotherapeutics||Mar 2020||1080||Collaboration agreement for Pellino inhibitor pipeline using AI|
Atomwise and Bridge Biotherapeutics announced a research collaboration to launch up to 13 small molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
Atomwise will use its AI technology and homology modeling capabilities to evaluate Pellino E3 ubiquitin ligases and their interactions with target protein substrates.
Atomwise and Bridge will rapidly cycle through the design and testing of potent small molecule compounds, evaluating billions of possibilities that will selectively inhibit Pellino proteins.
Atomwise will receive upfront, milestone, and royalty payments upon success of each research program.
Based upon historical averages for small molecule drugs, Atomwise estimates that it could receive up to $1.08B (including royalties) with success in all research programs.
|Bayer, Recursion||Sep 2020||1050||Collaboration, option and licensing agreement for digital drug discovery and therapies for fibrotic diseases|
Bayer and Recursion Pharmaceuticals have entered into a strategic collaboration agreement.
The partnership will leverage Recursion’s purpose-built artificial intelligence-guided drug discovery platform and Bayer’s small molecule compound library and deep scientific expertise to discover and develop new treatments for fibrotic diseases of the lung, kidney, heart and more.
In addition, Leaps by Bayer, the impact investment arm of Bayer, is leading Recursion’s Series D financing with an investment of USD 50 million.
Under the terms of the agreement, the parties may initiate more than ten programs with possible development and commercial milestone payments of more than USD 100 million per program plus royalties on future sales.
Bayer will gain the option to exclusively license novel therapeutics derived from the research activities.
Bayer will contribute with its small molecule compound library and expertise in biology and medicinal chemistry.
In addition to the USD 50 million equity investment, Recursion will receive an upfront payment of USD 30 million.
|Arrowhead Pharmaceuticals, Takeda Pharmaceutical||Oct 2020||1040||Co-development and co-promotion agreement for ARO-AAT for alpha-1 antitrypsin-associated liver disease|
Takeda Pharmaceutical and Arrowhead Pharmaceuticals announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD).
ARO-AAT is a potential first-in-class therapy designed to reduce the production of mutant alpha-1 antitrypsin protein, the cause of AATLD progression.
Takeda and Arrowhead will co-develop ARO-AAT which, if approved, will be co-commercialized in the United States under a 50/50 profit-sharing structure.
Outside the U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20-25% on net sales.
Arrowhead will receive an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million.
|Boehringer Ingelheim, Enleofen Bio||Jan 2020||1000||Licensing agreement for preclinical interleukin-11 (IL-11) platform|
Boehringer Ingelheim and Enleofen Bio announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases.
The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway.
The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases.
Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies.
Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones.
|Jnana Therapeutics, Roche||Jul 2020||1000||Collaboration agreement for regulators of cellular metabolism to treat immune-mediated and neurological diseases|
Jnana Therapeutics announced a strategic, multi-target collaboration and license agreement with Roche for the discovery of small molecule drugs directed at the solute carrier family of metabolite transporters as a broad, innovative approach for modulating cellular metabolism to treat immune-mediated and neurological diseases.
Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and commercialize exclusively.
Jnana will receive an upfront payment of $40 million in cash, and may receive research funding, preclinical, development and commercialization milestone payments, as well as royalties.
The aggregate value of potential future payments to Jnana can exceed $1 billion.
|Kiadis Pharma, Sanofi||Jul 2020||986.7||Licensing agreement for K-NK-cell programs|
Kiadis Pharma announced the exclusive license of Kiadis’ previously undisclosed K-NK004 program to Sanofi.
The agreement covers Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutic for combination with anti-CD38 monoclonal antibodies, including Sarclisa, Sanofi’s recently approved therapy for patients with multiple myeloma.
Sanofi has obtained exclusive rights to use Kiadis’ K-NK platform for two undisclosed pre-clinical programs.
Kiadis will receive a €17.5 million up front payment and will be entitled to receive up to €857.5 million upon Sanofi’s achievement of preclinical, clinical, regulatory and commercial milestones.
Kiadis will also receive up to low double-digit royalties based on commercial sales of approved products resulting from this agreement.
|Carmine Therapeutics, Takeda Pharmaceutical||Jun 2020||900||Collaboration, option and licensing agreement for rare disease gene therapies using novel red blood cell extracellular vesicles platform|
Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine's REGENT technology, based on red blood cell extracellular vesicles.
Takeda has committed a $5M convertible loan in support of the development of Carmine's novel REGENT platform.
Carmine will receive an upfront payment, research funding support and is eligible for over $900M in total milestone payments plus tiered royalties.
Takeda has an option to license the programs following the completion of pre-clinical proof of concept studies and would be responsible for clinical development and commercialization.
|Adaptimmune, Astellas Pharma, Universal Cells||Jan 2020||897.5||Co-development and co-promotion agreement for stem-cell derived allogeneic T-cell therapies|
Astellas Pharma, through its wholly-owned subsidiary Universal Cells, and Adaptimmune Therapeutics have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets.
These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune.
The collaboration will leverage Adaptimmune's target identification and validation capabilities for generating target-specific T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently of the HLA profile of the tumor cell.
The collaboration will also utilize Astellas’ Universal Donor Cell and Gene Editing Platform it obtained through the acquisition of Seattle-based Universal Cells.
Astellas will fund research up until completion of a Phase 1 trial for each candidate.
Upon completion of the Phase 1 trial for each candidate, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of the candidate, or to allow the other Party to pursue the candidate independently through a milestone and royalty bearing licence, with the agreement allowing for either company to opt out.
The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy.
If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party.
Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates independently.
Astellas will have sole rights to develop and commercialize these products, subject to necessary licenses and the payment of milestones and royalties.
Adaptimmune may receive up to $897.5 million in payments, including:
An upfront payment of $50 million.
Development milestones totalling up to $73.75 million for each product if the collaboration product discovered in this partnership is co-developed and commercialized by both companies
Up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Astellas.
Adaptimmune will receive research funding of up to $7.5 million per year.
Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits.
Astellas may receive up to $552.5 million, including:
Up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Adaptimmune.
Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits.
To the extent that Astellas and Adaptimmune co-develop and co-commercialize any T-cell therapy, they will equally share the costs of such co-development and co-commercialization, with the resulting profits from co-commercialization also shared equally.
Further details governing co-development and co-commercialization will be articulated in a product-specific commercialization agreement.
|Merck and Co, Zymeworks||Jul 2020||891||Research and licensing agreement for multispecific antibodies|
Zymeworks and Merck have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms.
Zymeworks will provide Merck a worldwide, royalty-bearing license to research, develop and commercialize up to three new multispecific antibodies toward Merck’s therapeutic targets.
Zymeworks will receive an undisclosed upfront payment and if each of the three programs yield an approved product, Zymeworks is eligible to receive up to US$411 million in option exercise fees and clinical development and regulatory approval milestone payments and up to US$480 million in commercial milestone payments, as well as tiered royalties on worldwide sales.
Merck will also receive a worldwide, royalty-bearing license to research, develop and commercialize up to three multispecific antibodies in the animal health field in exchange for additional milestone payments and tiered royalties.
|Evox Therapeutics, Takeda Pharmaceutical||Mar 2020||882||Collaboration and option agreement for multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies|
Evox Therapeutics announced the signing of a rare disease-focused partnership with Takeda Pharmaceutical.
The multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies, including Evox's preclinical programme in Niemann-Pick disease type C (NPC) and a second new programme directed at another undisclosed rare disease.
As part of the deal, Takeda also has the option to select up to three additional rare disease targets.
The partnership with Takeda enables Evox to continue advancing its proprietary exosome-based targeting and delivery technology, while also leveraging Takeda's extensive development and clinical expertise to advance these partnered programmes into the clinic.
Evox will be eligible to receive up to $44 million in upfront, near-term milestone payments and research funding.
Evox is eligible to receive approximately $882 million in upfront, development, and commercial milestone payments from Takeda.
Evox will also receive tiered royalties on net sales of each product.
Evox will be primarily responsible for research and development activities for each programme until IND-enabling studies and for manufacturing up to and including Phase 1 clinical trials.
Takeda will reimburse Evox for manufacturing costs incurred after the pre-clinical handover of the programmes.
|Eli Lilly, Sitryx||Mar 2020||880||Collaboration and licensing agreement for immunometabolic medicines|
Eli Lilly announced an exclusive global licensing and research collaboration with Sitryx.
The collaboration will study up to four novel preclinical targets identified by Sitryx that could lead to potential new medicines for autoimmune diseases.
Sitryx will receive an upfront payment of $50 million and Lilly will make a $10 million equity investment in Sitryx.
Sitryx will be eligible to receive potential development milestones up to $820 million, as well as commercialization milestones and royalty payments on potential sales in the mid- to high-single digit range.
In return, Sitryx will grant Lilly an exclusive, worldwide license to develop and commercialize up to four novel immunometabolism targeted therapeutics, including Sitryx's two lead projects.
Lilly and Sitryx will establish a 5-year research collaboration to support the development of the therapeutics, with Sitryx responsible for drug discovery, while Lilly will fund and manage the clinical development and commercial phase of the collaboration.
|Hanmi Pharmaceutical, Merck and Co||Aug 2020||870||Licensing agreement for Efinopegdutide|
Merck and Hanmi Pharmaceutical have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis (NASH).
Merck will be granted an exclusive license to develop, manufacture and commercializeefinopegdutidein the United States and globally.
Hanmi will receive an upfront payment of $10 million and is eligible to receive milestone payments up to $860 million associated with the development, regulatory approval and commercialization of efinopegdutide,as well as double-digit royalties on sales of approved product.
Hanmi retains an option to commercialize efinopegdutide in Korea.
|Abbvie, Alpine Immune Sciences||Jun 2020||865||Development, option and licensing agreement for ALPN-101|
Alpine Immune Sciences and AbbVie announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.
Alpine will receive an upfront payment of $60 million, and will also be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones.
Alpine is eligible to receive tiered royalties on net sales of ALPN-101.
AbbVie will receive an option to an exclusive license for ALPN-101.
During the option period, Alpine will conduct a phase 2 study in systemic lupus erythematosus.
Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.
|Hypera Pharma, Takeda Pharmaceutical||Mar 2020||825||Asset purchase agreement for over-the-counter and prescription pharmaceutical products|
Takeda Pharmaceutical has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera for a total value of $825M USD.
The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Growth & Emerging Markets Business Unit.
The non-core products in this latest transaction generated revenues of approximately $215 million USD in Fiscal Year 2018, driven by sales of key products such as Neosaldina, Nesina, and Dramin.
Takeda has entered into an agreement to divest the rights, title, and interest to the products in a portfolio of approximately 18 select OTC and prescription pharmaceutical assets sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru - to Hypera Pharma for a total value of $825M USD.
Takeda anticipates that approximately 300 commercial employees supporting the divested assets will be given the opportunity to transition over to Hypera Pharma at the close of this transaction.
Takeda and Hypera Pharma have also entered into a manufacturing and supply agreement under which Takeda will continue to manufacture these products and supply them to Hypera Pharma.
The transaction is expected to close in the second half of 2020, subject to the satisfaction of customary closing conditions.
Until then, Takeda remains the owner of these products and responsible for ensuring patient access to them.
|Gilead Sciences, Jounce Therapeutics||Sep 2020||805||Licensing agreement for JTX-1811 program|
Gilead Sciences announced an agreement with Jounce Therapeutics to exclusively license its JTX-1811 program.
JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells.
Gilead will make a $85 million upfront payment to, and a $35 million equity investment at a premium in, Jounce upon closing.
Jounce may receive up to an additional $685 million in future clinical, regulatory and commercial milestone payments.
Jounce will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments.
Jounce will lead development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop JTX-1811.
|Novartis, Sangamo BioSciences||Jul 2020||795||Collaboration, option and licensing agreement for genomic medicines for autism and other neurodevelopmental disorders|
Sangamo Therapeutics has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders.
The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders.
Under the terms of the agreement, over a three-year collaboration period, Novartis has exclusive rights to ZFP-TFs targeted to three undisclosed genes which are associated with neurodevelopmental disorders, including ASD and intellectual disability.
Novartis also has the option to license Sangamo’s proprietary AAVs.
Sangamo is responsible for certain research and associated manufacturing activities, all of which will be funded by Novartis, and Novartis assumes responsibility for additional research activities, investigational new drug-enabling studies, clinical development, related regulatory interactions, manufacturing and global commercialization.
Novartis will pay Sangamo a $75 million upfront license fee payment within thirty days.
Sangamo is eligible to earn up to $720 million in other development and commercial milestone payments, including up to $420 million in development milestones and up to $300 million in commercial milestones.
Sangamo is also eligible to receive from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.
|Aspen Pharmacare Canada, Mylan Laboratories||Sep 2020||761||Asset purchase agreement for thrombosis business|
Mylan announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings thrombosis business in Europe for EUR 641.9 million, subject to customary closing conditions and European regulatory clearances.
The transaction is expected to be immediately accretive to Mylan upon closing and is anticipated to be accretive to VIATRIS upon the completion of Mylan's previously announced combination with Upjohn that is expected to close in the fourth quarter of 2020.
Upon closing of the transaction, Mylan expects to fund an upfront payment of EUR 263.2 million to Aspen from existing cash.
Also, Mylan expects to utilize cash generated from operations to make the final deferred payment of EUR 378.7 million on June 25, 2021.
The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
|BioNTech, Pfizer||Mar 2020||748||Co-development and distribution agreement for potential COVID-19 vaccine|
BioNTech and Pfizer disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.
Collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved.
The collaboration will leverage Pfizer’s broad expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.
The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites.
BioNTech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance.
During the clinical development stage, BioNTech and its partners will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.
BioNTech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic.
BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is already covered by BioNTech’s collaboration with Fosun Pharma) upon regulatory approval.
Pfizer will pay BioNTech $185 million in upfront payments, including a cash payment of $72 million and an equity investment of $113 million.
BioNTech is eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million.
Pfizer and BioNTech will share development costs equally. Initially, Pfizer will fund 100 percent of the development costs, and BioNTech will repay Pfizer its 50 percent share of these costs during the commercialization of the vaccine.
Pfizer and BioNTech have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection.
The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.
The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020.
The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and BioNTech entered in 2018 to develop mRNA-based vaccines for prevention of influenza.
The companies expect to utilize multiple research and development sites from both companies, including in the United States and Germany, to house the activities identified by the collaboration agreement.
The companies will begin collaborating immediately.
They will finalize details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialization over the next few weeks.
|Selecta Biosciences, Swedish Orphan Biovitrum||Jun 2020||730||Licensing agreement for SEL-212|
Swedish Orphan Biovitrum and Selecta Biosciences have entered into a strategic licensing agreement for the product candidate SEL-212.
SEL-212 is a combination of Selecta’s tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase) that is designed to durably control serum uric acid, reduce immunogenicity, and allow for repeated monthly dosing for the treatment of chronic refractory gout.
Sobi will assume responsibility for development, regulatory, and commercial activities for SEL-212 in all markets outside of China.
Sobi will make initial payments to Selecta of USD 100 million, which include USD 75 million up-front license fee and USD 25 million in a private placement of shares of Selecta common stock.
Selecta is eligible to receive potential milestone payments of up to USD 630 million from Sobi, which are dependent upon specific regulatory and development targets having been met, as well as sales thresholds.
Selecta is eligible to receive tiered double-digit royalties on net sales.
Sobi and Selecta have entered into a share purchase agreement, pursuant to which Sobi will invest USD 25 million in a private placement of 5,416,390 shares of Selecta common stock at a purchase price of USD 4.62 per share (representing a 20% premium to the volume weighted average price over the 10 days prior to signing).
|Genentech, Vaccibody||Oct 2020||715||Collaboration and licensing agreement for VB10.NEO, individualized neoantigen cancer vaccines|
Vaccibody has entered into an exclusive worldwide license and collaboration agreement with Genentech for the development and commercialization ofDNA-based individualized neoantigen vaccines for the treatment of cancers.
Vaccibody will conduct development through the end of Phase 1b and Genentech will be responsible for development and commercialization thereafter.
The transaction will combine Genentech’s global cancer immunotherapy research, development and commercial leadership with Vaccibody’s targeted DNA-based vaccine platform to realize a potential new treatment paradigm of individualized cancer vaccines.
Vaccibody will receive USD 200 million in initial upfront and near-term payments. Additionally, Vaccibody will be eligible to receive up to a furtherUSD 515 million in potential payments and milestones, plus low double-digit tiered royalties on sales of commercialized products arising from the partnership.
Following completion of the Phase 1b study, Genentech will have responsibility and bear all costs for clinical, regulatory, manufacturing and commercialization activities.
Genentech and Vaccibody will progress Vaccibody’s investigationalproduct, VB10.NEO, into clinical trials in the U.S. and in Europe.
VB10.NEO, an individualized DNA-based neoantigen vaccine, uniquely targets encoded antigens to antigen presenting cells which are essential for generating potent T cell responses required for cancer therapy.
The vaccine is designed to be produced on-demand according to the neoantigen profile of an individual patient.
Neoantigens are proteins generated by tumor-specific mutations not present in normal tissues, and are thus an attractive target for cancer immunotherapy asthey may be recognized as foreign by the immune system.
|Biogen, Pfizer||Jan 2020||710||Licensing agreement for PF-05251749|
Biogen announced an agreement to acquire from Pfizer PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases.
Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD).
The purchase will include an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.
|Kyowa Hakko Kirin, MEI Pharma||Apr 2020||682.5||co-development, co-promotion and licensing agreement for ME-401|
MEI Pharma and Kyowa Kirin have entered into a global license, development and commercialization agreement to further develop and commercialize MEI's ME-401, an oral, once-daily, investigational drug-candidate, selective for phosphatidylinositol 3-kinase delta (PI3Kδ), in clinical development for the treatment of B-cell malignancies.
MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales.
Kyowa Kirin has exclusive commercialization rights outside of the U.S.
Under the terms of the agreement, which substantially retains and consolidates the terms of the 2018 license agreement between MEI and Kyowa Kirin to develop and commercialize ME-401 in Japan, MEI will receive a $100 million upfront payment from Kyowa Kirin.
MEI is also eligible to receive up to $582.5 million in additional payments from Kyowa Kirin depending on the achievement of certain U.S. and ex-U.S. development, regulatory and commercial milestones.
If approved by FDA in the U.S., MEI and Kyowa Kirin will co-promote ME-401, with MEI booking all revenue from sales.
MEI and Kyowa Kirin will share U.S. profits and costs (including development costs) on a 50-50 basis.
Outside the U.S., Kyowa Kirin will have exclusive commercialization rights, lead commercialization and book all revenues from sales of ME-401.
Kyowa Kirin will pay MEI escalating tiered royalties on ex-U.S. sales starting in the teens.
Kyowa Kirin will be responsible for all incremental ex-U.S. clinical development costs and all ex-U.S. regulatory, CMC and commercial costs.
The companies have agreed to a development plan designed to broadly evaluate ME-401 in patients with various B-cell malignancies, including in combination with other agents.
|Laborie Medical Technologies, Urotronic||Oct 2020||680||Option and licensing agreement for Optilume|
Laborie Medical Technologies entered into a multi-faceted, strategic partnership with Urotronic to support regulatory approval of Optilume, a drug-coated balloon (DCB) technology for use in urethral strictures and benign prostatic hyperplasia (BPH).
LABORIE will invest $15 million USD in Urotronic's Series C financing along with $5 million USD from current shareholders and secure an option to acquire all rights to Optilume.
Under the terms of the option agreement, LABORIE can acquire a perpetual, exclusive license to the Optilume Urethral Strictures device, upon FDA approval, for $165 million.
LABORIE also has an option to acquire the Company, upon FDA approval of the Optilume BPH device, for $350 million upfront plus another $150 million in earnouts if certain sales milestones are reached.
This strategic partnership with Urotronic demonstrates LABORIE's continued commitment to expand the use of less invasive treatments and improve outcomes for patients suffering from urological disorders.
|Elevar Therapeutics, Oasmia Pharmaceutical||Mar 2020||678||Licensing agreement for Apealea|
Elevar Therapeutics announced an agreement with Oasmia Pharmaceutical to obtain global rights for Apealea, except in Nordics, Russia, and certain countries in Eastern Europe.
Elevar and Oasmia have created a joint development committee for Apealea to expand approvals in Ovarian cancer worldwide while driving development in additional indications.
Although the full terms of the deal have not been disclosed, Oasmia will receive an upfront payment of $20M and up to $658M in additional regulatory and sales milestones.
|Empirico, Ionis Pharmaceuticals||Jan 2020||660||Collaboration agreement for Discovery and development of novel antisense oligonucleotide therapeutics|
Empirico has entered into a strategic collaboration with Ionis Pharmaceuticals.
During the three-year collaboration, Empirico will utilize its Precision Insights Platform, which incorporates huge biological data sets, human genetics and advanced algorithmic approaches, to identify therapeutic targets for indications and tissues that are amenable to Ionis’ industry-leading antisense technology.
Ionis can advance up to ten targets identified by Empirico and assume responsibility for all preclinical and clinical development activities.
Empirico and Ionis will also work together to incorporate human genetics evidence into ongoing efforts with existing Ionis programs, including work on target validation, indication and biomarker selection, and patient stratification.
Ionis has made a $10 million equity investment in Empirico, with additional near-term commitments of up to $30 million based on operational and preclinical milestones.
Empirico will be eligible to receive in excess of $620 million for the achievement of clinical development, regulatory and commercial milestones, and royalties on net sales.
Empirico also has the option to license, develop, and commercialize an Ionis development candidate directed toward a collaboration target for which Ionis will receive milestone payments and royalties on net sales.
|PTC Therapeutics, Royalty Pharma||Jul 2020||650||Royalty financing agreement for Risdiplam|
Royalty Pharma announced an agreement with PTC Therapeutics to acquire a portion of PTC’s royalty interest in risdiplam for a one-time payment of $650 million.
|Biomedical Advanced Research and Development Authority, Emergent BioSolutions, US Government||Jun 2020||628||Contract service agreement for COVID-19 vaccine development and manufacturing|
Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines.
This task order, valued at approximately $628 million, is being issued under the company’s 2012 contract with BARDA that established Emergent’s Baltimore Bayview facility as a Center for Innovation in Advanced Development and Manufacturing (CIADM) for pandemic preparedness, and expands the partnership to include investments in Emergent’s Baltimore Camden and Rockville facilities, creating a U.S.-based manufacturing supply chain for pharmaceutical and biotechnology innovators of COVID-19 vaccine candidates.
Under the task order, Emergent will deploy its molecule-to-market CDMO offering, committing manufacturing capacity, valued at approximately $542.7 million, for production of COVID-19 vaccine candidates through 2021.
This award secures, on behalf of leading COVID-19 vaccine innovators that are supported by the U.S. government, capacity for drug substance manufacturing at the company’s Baltimore Bayview facility and for drug product manufacturing at the Baltimore Camden and Rockville locations.
The task order also includes an investment of approximately $85.5 million for the rapid expansion of Emergent’s viral and non-viral CDMO drug product fill/finish capacity at the Baltimore Camden and Rockville facilities.
|Esperion Therapeutics, Otsuka||Apr 2020||610||Development and licensing agreement for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Tablets|
Esperion have entered into a collaboration agreement with Otsuka Pharmaceutical for the development and commercialization of NEXLETOL and NEXLIZET tablets in Japan.
Both medicines were recently approved in both the US and EU.
The collaboration advances the commitment of both companies to provide cost-effective, oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicines for hypercholesterolemia patients in Japan.
This development and commercialization collaboration combines Esperion’s expertise in lipid management with Otsuka’s deep cardiovascular drug development and commercialization expertise in Japan.
Esperion will grant Otsuka exclusive rights to NEXLETOL and NEXLIZET tablet development and commercialization in Japan.
Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan.
Otsuka will fund all Japan-specific development costs associated with the program.
Esperion estimates this amount to total up to $100 million over the next few years.
Esperion will receive an upfront cash payment of $60 million as well as up to an additional $450 million in total development and sales milestones.
Esperion will also receive tiered royalties from 15 percent to 30 percent on net sales in Japan.
|Gilead Sciences, Kite Pharma, Kyverna Therapeutics||Jan 2020||587.5||Collaboration and licensing agreement for engineered T cell therapies|
Kyverna has entered into a strategic collaboration and license agreement with Gilead to develop engineered T cell therapies for the treatment of autoimmune disease based on Kyverna's synthetic Treg platform and synNotch technology from Kite.
Kyverna will be responsible for conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option, upon the exercise of which Gilead will be solely responsible for further clinical development and commercialization efforts for these programs.
Gilead will make to Kyverna an upfront payment of $17.5 million and Kyverna may earn an additional $570 million in development and commercialization milestones.
Kyverna will also continue to advance its platform and develop proprietary programs beyond the Gilead collaboration.
|LEO Pharma, Microbio Shanghai, Oneness Biotech||Apr 2020||570||Licensing agreement for FB825|
LEO Pharma has signed a worldwide exclusive licensing agreement with Oneness Biotech and Microbio Shanghai covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.
LEO Pharma will make an upfront payment of USD 40 million and offer milestone payments up to USD 530 million, followed by a tiered high single-digit to double-digit royalties.
Oneness will be responsible for executing the Phase 2a study for Atopic Dermatitis in the United States and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China.
LEO Pharma will assume all the development responsibilities after the Phase 2a studies.
|Cheplapharm Arzneimittel, Takeda Pharmaceutical||Sep 2020||562||Asset purchase agreement for cardiovascular, metabolic and anti-inflammatory therapeutic products|
Takeda Pharmaceutical has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm.
Takeda will receive an upfront payment of approximately $562 million USD, subject to customary legal and regulatory closing conditions.
The portfolio to be divested to Cheplapharm is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories sold predominantly in Europe and Canada.
This includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium.
The portfolio generated FY 2019 net sales of approximately $260 million USD.
While the products included in the sale address key patient needs in these countries, they are outside of Takeda’s five key business areas.
There are no anticipated employee transfers in connection with this transaction.
The transaction is expected to close by the end of Fiscal Year 2020 (ending March 2021), subject to the satisfaction of customary closing conditions and receipt of required regulatory clearances.
Until then, the products will continue to be made available to patients and manufactured and supplied by Takeda.
|AstraZeneca, Samsung Biologics||Sep 2020||545.6||Manufacturing and supply agreement for drug substance|
Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million.
Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca's biologics therapeutics, which could be increased to $545.6 million.
By leveraging Samsung Biologics' robust expertise and capabilities in the manufacturing of high-quality biopharmaceuticals, this new partnership will enable AstraZeneca to expand its biologics manufacturing capabilities into Asia Pacific.
According to AstraZeneca, this collaboration agreement is also expected to accelerate Korean bio-health innovation.
|Assembly Biosciences, BeiGene||Jul 2020||540||Collaboration and licensing agreement for ABI-H0731, ABI-H2158 and ABI-H3733|
Assembly Biosciences and BeiGene have entered into a collaboration in China for Assembly’s portfolio of three clinical-stage core inhibitor candidates for the treatment of patients with chronic hepatitis B virus (HBV) infection.
Assembly has granted BeiGene exclusive rights to develop and commercialize ABI-H0731, ABI-H2158 and ABI-H3733 in China, including Hong Kong, Macau, and Taiwan.
ABI-H0731 and ABI-H2158 are both in ongoing Phase 2 clinical trials and ABI-H3733 is in Phase 1 development.
BeiGene will be responsible for development, regulatory submissions, and commercialization in China.
Assembly retains full worldwide rights outside of the partnered territory for the Company’s HBV portfolio.
Assembly will receive an upfront cash payment of $40 million and is eligible to receive up to approximately $500 million in potential development, regulatory and net sales milestone payments pending successful development and commercialization of the licensed candidates.
Assembly is eligible to receive tiered royalties of net sales.
BeiGene will contribute initial funding for clinical development in China, after which the development costs for the territory will be shared equally by the parties.
|BridgeBio Pharma, LianBio||Aug 2020||531.5||Collaboration agreement for targeted oncology drug candidates|
BridgeBio Pharma is partnering with LianBio.
The partnership marks the first major expansion of BridgeBio’s pipeline into Asian markets.
This strategic relationship will initially focus on two of BridgeBio’s targeted oncology drug candidates, FGFR inhibitor infigratinib, currently in Phase 3 development for FGFR-driven tumors and Phase 1-ready SHP2 inhibitor BBP-398, for tumors driven by RAS and receptor tyrosine kinase mutations.
The agreement also provides LianBio with preferential future access in the territory to more than 20 drug development candidates currently owned or controlled by BridgeBio.
This collaboration is designed to advance and accelerate BridgeBio’s programs in China and other major Asian markets, allowing BridgeBio to quickly bring innovation to large numbers of patients with high unmet need.
LianBio will receive commercial rights in China and selected Asian markets and participate in clinical development activities for infigratinib (housed in BridgeBio affiliate QED) and BBP-398 (housed in BridgeBio affiliate Navire).
BridgeBio’s near-term economics includes a total of $26.5 million in upfront and milestone payments.
BridgeBio will receive up to $505 million in future milestone payments, tiered royalty payments from single- to double-digits on net sales of both products in licensed territories.
BridgeBio will increase its equity interest via investment in LianBio and BridgeBio CEO Neil Kumar has been appointed to the LianBio board of directors.
|Supernus Pharmaceuticals, US WorldMeds||Apr 2020||530||Asset purchase agreement for CNS portfolio|
Supernus Pharmaceuticals has entered into a definitive agreement under which Supernus will acquire the CNS portfolio of US WorldMeds.
With the acquisition, Supernus adds three established and marketed products in the U.S. market with a product candidate in late-stage development:
APOKYN (apomorphine hydrochloride) injection is used, as needed, to provide rapid, reliable, and robust control of body movements in people with Parkinson’s disease (PD) when they experience an off episode. An off episode, also called hypomobility, may include symptoms such as muscle stiffness, slow movements, and difficulty starting movements.
MYOBLOC® (rimabotulinumtoxinB) injection is the first and only approved botulinum toxin Type B injectable indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults, and the treatment of chronic sialorrhea in adults.
XADAGO® (safinamide) tablets is a monoamine oxidase type B (MAO-B) inhibitor indicated as a daily adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes.
Apomorphine Infusion Pump is a product candidate for the continuous treatment of motor fluctuations (“on‐off” episodes) in PD patients whose motor control is unsatisfactory with oral levodopa and at least one other noninvasive PD therapy. New Drug Application (NDA) submission is expected in the second half of 2020 with potential launch, if approved by the FDA, in the second half of 2021.
Total consideration of $530 million consists of an upfront cash payment of $300 million plus regulatory and commercial milestone cash payments up to $230 million.
All cash consideration will be funded through existing balance sheet cash.
|Navitor Pharmaceuticals, Supernus Pharmaceuticals||Apr 2020||525||Co-development and option agreement for mTORC1 Activator NV-5138|
Supernus Pharmaceuticals and Navitor Pharmaceuticals announced a joint development and option agreement for Navitor’s mTORC1 activator, NV-5138.
Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in TRD.
Supernus will pay the costs of Phase II development up to $50 million, plus certain costs associated with nonclinical development and formulation.
In addition, Navitor has granted Supernus an exclusive option to license or acquire NV-5138 in all world territories, excluding Greater China, prior to initiation of a Phase III clinical program.
In exchange for the option to license or acquire NV-5138, Navitor will receive an upfront payment of $25 million, composed of a $10 million option fee and a $15 million equity investment representing approximately 13% ownership in Navitor.
Total payments, exclusive of royalty payments on net sales of NV-5138 and development costs under the agreement, have the potential to reach $410 million to $475 million, which includes the upfront payment of $25 million, an additional license or acquisition fee depending on whether Supernus ultimately licenses or acquires NV-5138, and subsequent clinical, regulatory and sales milestone payments.
Supernus also will have the first right of refusal for any compound with a similar mechanism of action on mTORC1 as NV-5138 in the central nervous system.
In conjunction with the equity investment, Jack Khattar, President and CEO of Supernus, will join the Board of Directors of Navitor.
|ACADIA Pharmaceuticals, Vanderbilt University||May 2020||525||Research and licensing agreement for drug candidates targeting the muscarinic M1 receptor for range of central nervous system|
ACADIA Pharmaceuticals and Vanderbilt University announced an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of central nervous system (CNS) disorders.
The collaboration will focus on positive allosteric modulators (PAMs) of the M1 receptor.
The WCNDD has been developing highly selective PAMs of the M1 subtype of muscarinic acetylcholine receptor, which may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders.
The agreement includes a lead compound currently in Phase 1 testing, as well as compounds currently in preclinical development and compounds generated in an ongoing discovery program.
Vanderbilt University will receive $10 million upfront and is eligible for potential milestone payments of up to $515 million and tiered royalties.
|Merck KGaA, Novartis||Oct 2020||524||Licensing agreement for anti-ADAMTS5 nanobody for osteoarthritis|
Merck has entered into an out-licensing agreement with Novartis for the development of M6495, an anti-ADAMTS5 Nanobody for the potential treatment of osteoarthritis (OA).
Merck will out-license to Novartis the Phase II-ready asset M6495 for further evaluation in OA patients.
Merck will receive an upfront payment of € 50 million with the potential of receiving a further € 400 million related to delivering on certain development and commercial milestones and royalties on future net sales.
Novartis will assume full responsibility for the development and commercialization of the M6495 program.
|Pfizer, eFFECTOR Therapeutics||Jan 2020||507||Collaboration, licensing, option and co-promotion agreement for small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E)|
eFFECTOR Therapeutics and Pfizer announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E), a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways.
eIF4E is an effector protein that is activated in a variety of human cancers and is linked to poor prognosis and resistance to certain therapies.
eFFECTOR will receive a $15 million payment upfront, and will be eligible for additional potential $492M in R&D funding, development and sales milestone payments.
eFFECTOR will receive royalties on sales of any products that may result from this collaboration if the program reaches commercialization and has an option to enter into a co-promotion and profit and loss share arrangement in the United States.
|Merck and Co, Yumanity Therapeutics||Jun 2020||500||Collaboration and licensing agreement for treatments for neurodegenerative diseases|
Yumanity Therapeutics has entered into a strategic research collaboration and license agreement with Merck focused on accelerating the development of new treatments for neurodegenerative diseases.
Merck will gain exclusive rights to two novel Yumanity pipeline programs for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).
Yumanity and Merck will collaborate to advance the two preclinical programs during the research term, after which Merck has the right to continue clinical development and commercialization.
Yumanity will receive an upfront payment and is eligible to receive milestone payments totaling approximately $500M associated with the successful development of marketed products for pipeline programs, as well as royalties on net sales.
Merck is also joining existing Yumanity investors (Fidelity Management & Research Company, Redmile Group, Pfizer Ventures, Alexandria Venture Investments, Tony Coles, and Dolby Family Ventures) by participating in a Series C round of financing.
|Engitix, Takeda Pharmaceutical||Aug 2020||500||Collaboration and licensing agreement for anti-fibrotic therapies in advanced liver diseases|
Engitix entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis.
Engitix and Takeda will collaborate in the confirmation and validation of targets and preclinical development of therapeutics in liver fibrosis using Engitix’s unique extracellular matrix (ECM) discovery platform.
Takeda will have exclusive rights to develop and commercialise clinical candidates generated against validated targets derived from the collaboration.
Engitix will receive an upfront payment, with additional near-term payments based on the confirmation and functional validation of selected targets.
Engitix will be eligible to receive more than $500 million for the achievement of preclinical, development, regulatory and commercial milestones, as well as further royalty payments upon sales of commercialised products.
|Boehringer Ingelheim, Click Therapeutics||Sep 2020||500||Collaboration, development and licensing agreement for CT-155|
Boehringer Ingelheim and Click Therapeutics have entered into a collaboration for the development and commercialization of a prescription-based digital therapeutic.
It will utilize cognitive and neurobehavioral mechanisms delivered through Click’s proprietary engagement platform with the goal of reducing cognitive deficits and impaired social functioning in patients with schizophrenia.
Together the two companies will join their expertise to develop a novel mobile application, CT-155, which combines multiple clinically validated therapeutic interventions to help schizophrenia patients modify their behavior to achieve positive clinical outcomes alone and in combination with pharmaceutical therapy options.
The partnership aims to provide better tools and resources to those living with schizophrenia, where there remains a huge unmet need due to lack of access to psychosocial intervention therapies.
Click Therapeutics will be primarily responsible for research and development activities, and will support Boehringer Ingelheim as it undertakes worldwide commercialization activities.
Click Therapeutics will receive under the terms of the partnership agreement an upfront payment and funding for research and development activities as well as clinical, regulatory and commercial milestones representing a total deal value of over USD 500 million.
Click Therapeutics will receive tiered royalties on annual net sales of CT-155 worldwide.